Zalgen Labs is a biotechnology company specializing in the design and production of superior biological molecules critical for the development and commercialization of immunotherapeutics, novel vaccines, and reliable, rapid, and affordable diagnostic platforms targeting neglected and underrepresented human infectious diseases. The company makes use of its proprietary expression platforms, including its patented mammalian cell-based biomanufacturing system, CHOLCelect, to deliver next generation biologicals to world health and biodefense settings.

The Company fully supports the Research Investigators’ Financial Conflict of Interest (“RIFCOI”) regulations, “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” (42 CFR Part 50, Subpart F) and “Responsible Prospective Contractors” (45 CFR Part 94), which apply to some of its work. Zalgen’s RIFCOI Policy is available at this link.